Clinical trial · people

Abaloparatide: bone formation up on every surface tested at 3 months

Checked against the paper Clinical trialPublished by PepVault

The takeaway

Abaloparatide started measurable new bone formation across every bone surface studied within 3 months, through both remodeling and modeling, though this study does not show a fracture benefit on its own.

Kind
Clinical trial
Studied in
People
Number studied
23
Published
2021
Journal
J Bone Miner Res

What they tested

The team wanted to see how early abaloparatide starts new bone formation, and whether that new bone comes from remodeling, modeling or both.

How the study was done

An open-label, single-arm study in 23 postmenopausal women with osteoporosis, all given the trial's 80 μg daily dose with no control group. Bone-labeling dyes were given before treatment and again before a transiliac bone biopsy at 3 months, so changes from baseline could be measured.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

After 3 months, median mineralizing surface, a measure of how much bone surface is actively forming, rose to 24.7%, 48.7%, 21.4% and 16.3% of total surface. Those were 5.5-, 5.2-, 2.8- and 12.9-fold changes on the cancellous (spongy inner bone), endocortical (inner face of the outer shell), intracortical (inside the shell) and periosteal (outer face) surfaces, each a significant rise over baseline. Bone formation rate went up on every surface measured, while mineral apposition rate went up only on intracortical surfaces. Modeling-based formation, meaning new bone laid down without first being broken down, made up 37% of the rise in bone-forming surface on endocortical bone and 23% on cancellous bone, and blood markers of bone turnover at month 1 or month 3 generally tracked the biopsy changes.

What it doesn’t show

This was a small, open-label study with no comparison group and only 3 months of treatment. It measured bone formation in biopsies, not fractures or bone density.

The paper

Dempster et al. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2021.

The compound

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo